ZTS · Zoetis Inc. · Metrics
Market Cap
$30.29B
Shares
413.22M
ZTS metrics
83 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$73.31
Market cap
$30.29B
Price action
20 metricsPrice change (1W)
-4.8%
Price change (30D)
-1.7%
Price change (3M)
-10.5%
Price change (6M)
-38.9%
Price change (YTD)
-41.5%
Price change (1Y)
-51.5%
Trailing year
Price change (5Y)
-64.9%
52-week high
$151.75
52-week low
$71.86
Change from 52-week high
-51.5%
Change from 52-week low
+2.4%
Annualized volatility
37.7%
Annualized volatility (3M)
33.8%
Beta
0.6
RSI (14D)
42.5
Price vs SMA 50
-2.6%
Price vs SMA 200
-28.5%
Avg volume (3M)
6.31M
Relative volume
0.9
Average dollar volume
$480.84M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
413.22M
Valuation
12 metricsP / E (TTM)
12.0
Trailing earnings · reciprocal yield 8.3%
PEG ratio
9.8
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.4%
P / book
10.0
reciprocal yield 10.0%
FCF yield
7.4%
TTM · current market cap
Buyback yield
11.6%
P / FCF
13.5
reciprocal yield 7.4%
P / operating cash flow
11.0
reciprocal yield 9.1%
Earnings yield
8.4%
Historical valuation
8 metricsP / E historical average (3Y)
27.8×
reciprocal yield 3.6%
P / E historical average (5Y)
32.4×
reciprocal yield 3.1%
EV / revenue historical average (3Y)
9.0×
reciprocal yield 11.1%
EV / revenue historical average (5Y)
10.0×
reciprocal yield 10.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
2.8%
Trailing 12 months
Payout ratio
—
Shareholder yield
11.6%
Dividend / share (TTM)
$2.09
Dividend growth YoY
+8.2%
Dividend growth streak
5
Last ex-dividend
2026-07-20
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
71.7%
Operating margin
—
Trailing 12 months
Net margin
27.7%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
$2.64B
Trailing 12 months
Diluted EPS (TTM)
$6.12
FCF margin
24.3%
Effective tax rate
20.1%
Growth
11 metricsRevenue growth YoY
-0.2%
Year over year
Net income growth YoY
-4.8%
Revenue (TTM)
$9.53B
Trailing 12 months
EPS growth YoY
+1.2%
Shares change YoY
-6.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+5.4%
Revenue CAGR (5Y)
+7.2%
EPS CAGR (3Y)
+10.3%
EPS CAGR (5Y)
+12.0%
FCF CAGR (3Y)
+19.9%
FCF CAGR (5Y)
+6.4%
Quality
14 metricsReturn on equity
83.8%
Return on assets
17.5%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
—
Free cash flow (TTM)
$2.32B
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.48B
Total assets
$15.08B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$2.84B
Capital expenditures (TTM)
$524.00M
R&D (TTM)
$723.00M
SG&A (TTM)
$2.37B
Stock compensation (TTM)
$95.00M
R&D / revenue
7.6%
Stock compensation / revenue
1.0%
Ownership (13F)
3 metrics13F filers
1,423
13F filer change QoQ
-200
Institutional ownership
97.9%
Short interest
3 metricsShort interest
4.1%
Latest settlement · 2.0 days to cover
Days to cover
2.0d
Short-squeeze score
43 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1555280
CUSIP
98978V103
13F (30d)
578 filings
563 filers
Visit website
Investor relations